DK2111401T3 - 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer - Google Patents
4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancerInfo
- Publication number
- DK2111401T3 DK2111401T3 DK07865924.0T DK07865924T DK2111401T3 DK 2111401 T3 DK2111401 T3 DK 2111401T3 DK 07865924 T DK07865924 T DK 07865924T DK 2111401 T3 DK2111401 T3 DK 2111401T3
- Authority
- DK
- Denmark
- Prior art keywords
- fluorophenoxy
- methylpyridine
- pyrazol
- prodrugs
- carboxamide
- Prior art date
Links
- KDSSTZKZXAEHRH-UHFFFAOYSA-N 4-[4-[[5-tert-butyl-2-[3-(hydroxymethyl)phenyl]pyrazol-3-yl]carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3N(N=C(C=3)C(C)(C)C)C=3C=C(CO)C=CC=3)=CC=2)=C1 KDSSTZKZXAEHRH-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87583006P | 2006-12-20 | 2006-12-20 | |
| US98677307P | 2007-11-09 | 2007-11-09 | |
| PCT/US2007/088365 WO2008079968A1 (en) | 2006-12-20 | 2007-12-20 | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2111401T3 true DK2111401T3 (da) | 2011-05-30 |
Family
ID=39247683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07865924.0T DK2111401T3 (da) | 2006-12-20 | 2007-12-20 | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8101773B2 (da) |
| EP (1) | EP2111401B1 (da) |
| JP (1) | JP2010514691A (da) |
| CN (1) | CN101679362A (da) |
| AT (1) | ATE498620T1 (da) |
| AU (1) | AU2007336873A1 (da) |
| CA (1) | CA2673041A1 (da) |
| DE (1) | DE602007012589D1 (da) |
| DK (1) | DK2111401T3 (da) |
| IL (1) | IL199403A0 (da) |
| MX (1) | MX2009006579A (da) |
| WO (1) | WO2008079968A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| NZ553804A (en) * | 2004-09-29 | 2010-07-30 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
| WO2006094626A1 (en) | 2005-03-07 | 2006-09-14 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| CN102140093A (zh) * | 2010-02-03 | 2011-08-03 | 上海源力生物技术有限公司 | 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用 |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| LT2782584T (lt) | 2011-11-23 | 2021-09-10 | Therapeuticsmd, Inc. | Natūralios kombinuotos pakaitinės hormonų terapijos kompozicijos ir gydymas |
| EP2861589B1 (en) * | 2012-06-15 | 2017-05-17 | Basf Se | Multicomponent crystals comprising dasatinib and selected cocrystal formers |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| WO2014033446A1 (en) * | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| CN105012321A (zh) * | 2015-08-20 | 2015-11-04 | 中国人民解放军第三军医大学第三附属医院 | 替加环素在制备抗胶质瘤药物中的应用 |
| JP2019513709A (ja) | 2016-04-01 | 2019-05-30 | セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． | ステロイドホルモン薬学的組成物 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005110994A2 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| DE102005015253A1 (de) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | Pyrazolderivate |
| CA2631746A1 (en) * | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
-
2007
- 2007-12-20 DK DK07865924.0T patent/DK2111401T3/da active
- 2007-12-20 CN CN200780051553A patent/CN101679362A/zh active Pending
- 2007-12-20 MX MX2009006579A patent/MX2009006579A/es not_active Application Discontinuation
- 2007-12-20 DE DE602007012589T patent/DE602007012589D1/de active Active
- 2007-12-20 JP JP2009543220A patent/JP2010514691A/ja active Pending
- 2007-12-20 AT AT07865924T patent/ATE498620T1/de active
- 2007-12-20 WO PCT/US2007/088365 patent/WO2008079968A1/en not_active Ceased
- 2007-12-20 US US12/520,609 patent/US8101773B2/en not_active Expired - Fee Related
- 2007-12-20 CA CA002673041A patent/CA2673041A1/en not_active Abandoned
- 2007-12-20 EP EP07865924A patent/EP2111401B1/en not_active Not-in-force
- 2007-12-20 AU AU2007336873A patent/AU2007336873A1/en not_active Abandoned
-
2009
- 2009-06-17 IL IL199403A patent/IL199403A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008079968A1 (en) | 2008-07-03 |
| MX2009006579A (es) | 2009-07-22 |
| CN101679362A (zh) | 2010-03-24 |
| IL199403A0 (en) | 2010-03-28 |
| JP2010514691A (ja) | 2010-05-06 |
| ATE498620T1 (de) | 2011-03-15 |
| AU2007336873A1 (en) | 2008-07-03 |
| EP2111401A1 (en) | 2009-10-28 |
| EP2111401B1 (en) | 2011-02-16 |
| US20100063107A1 (en) | 2010-03-11 |
| CA2673041A1 (en) | 2008-07-03 |
| US8101773B2 (en) | 2012-01-24 |
| DE602007012589D1 (de) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2111401T3 (da) | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl}carbamoyl)-amino]-3-fluorphenoxy}-N-methylpyridin-2-carboxamid samt prodrug og salte heraf til behandling af cancer | |
| NO2023022I1 (no) | cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate | |
| PH12022551424A1 (en) | Kras g12c inhibitors. | |
| NO20081554L (no) | Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav | |
| ATE522509T1 (de) | Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase | |
| CY1117287T1 (el) | Πυρρολιδινονη ως αναστολεις metap-2 | |
| UA95641C2 (xx) | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы | |
| DK2054418T3 (da) | Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer | |
| CY1113386T1 (el) | Αναστολεις πρωτεασωματος | |
| CY1112142T1 (el) | Κυκλοπεντα [d] πυριμιδινες ως αναστολεις της κινασης πρωτεϊνης του ακτ | |
| WO2008079972A3 (en) | 4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer | |
| ATE493418T1 (de) | Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren | |
| EA200701467A1 (ru) | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) | |
| EA200900135A1 (ru) | Производные пиразола в качестве ингибиторов цитохрома р450 | |
| CY1112754T1 (el) | Μεθοδοι και ενδιαμεσα για την παρασκευη παραγωγων ν4-φαινυλ-κιναζολιν-4-αμινης | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| NO20076694L (no) | Sulfonamidforbindelser og anvendelser derav | |
| DK1937639T3 (da) | Pyridinaminosulfonyl-substituerede benzamider som inhibitorer af cytochrom P450 3A4 (CYP3A4) | |
| EA201100035A1 (ru) | Производные тиазолилпиперидина | |
| NO20080053L (no) | Etanolaminsalt av N-(3-metoksy-5-metylpyrazin-2yl)-2-(4-(1,3,4-oksadiazol-2-yl)fenyl)pyridin-3-sulfonamid | |
| WO2008011539A3 (en) | Anesthetic compounds | |
| ZA200904658B (en) | 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl} carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer | |
| HK1139382A (en) | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-chlorophenoxy}-n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer | |
| EA201990219A3 (ru) | Ингибиторы mek и способы их применения | |
| CY1115454T1 (el) | Παραγωγα πυριδιζινονης |